A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety OF ABP 215 Compared with Bevacizumab in Subjects with Advanced Non-Small Cell Lung Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms MAPLE
- Sponsors Amgen
- 31 May 2019 Results assessing central and investigator evaluation of efficacy of the bevacizumab biosimilar ABP 215 published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019)
- 07 Jan 2019 Results assessing efficacy & safety of Biosimilar ABP 215 in Patients with Advanced Non-small Cell Lung Cancer published in the Clinical Cancer Research
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer